Last updated: February 13, 2026
mmary:
The drug with NDC 62135-0819 is Vyvgart (efgartigimod alfa-fcab), produced by argenx, approved by the FDA in December 2021 for generalized myasthenia gravis (gMG). Current market assessments project stable growth driven by expanding indications and competitive dynamics, with prices expected to remain within the range of approximately $5,000 to $6,000 per dose.
What Is the Market Context for Vyvgart (NDC 62135-0819)?
Vyvgart is a monoclonal antibody targeting neonatal Fc receptor (FcRn), thereby reducing pathogenic IgG antibodies in autoimmune diseases. Approved for adult gMG patients who are anti-acetylcholine receptor (AChR) antibody positive, Vyvgart addresses a niche with high unmet medical need.
Market Size
- The global gMG market was valued at approximately $1.3 billion in 2022, with forecasts reaching $2 billion by 2027 ([1]).
- The U.S. accounts for about 60% of market revenue, roughly $780 million in 2022.
- Estimated prevalence in the U.S. is about 20,000-25,000 confirmed cases, with an annual diagnosis rate of approximately 2,000.
Competitive Landscape
- Existing treatments include thymectomy, corticosteroids, immunosuppressants, and plasma exchange.
- Novartis's Soliris (eculizumab) and other biologics like Zinbryta (daclizumab) serve as alternatives, though none target FcRn.
Market Adoption & Usage
- Vyvgart's dosing involves monthly IV infusions, generating recurring revenue streams.
- Adoption is driven by its efficacy and safety profile compared to older therapies.
What Are the Price Projections for NDC 62135-0819?
Current Pricing
- Estimated list price per infusion ranges from $5,250 to $6,000.
- Average annual therapy cost for a typical patient is approximately $60,000 to $70,000, assuming 11-14 infusions per year.
Price Trends
- Despite pressure for discounts in the biotech sector, Vyvgart's pricing remains stable due to its niche market and clinical benefits.
- Price reductions are unlikely before broader indications or biosimilars enter the market.
Future Price Potential
- Introduction of additional indications (e.g., chronic immune thrombocytopenia) could expand revenue but may pressure pricing.
- Market competition with next-generation FcRn inhibitors (e.g., Idesy’s Rozanolixizumab) could moderate prices over 3-5 years.
Factors Influencing Price Dynamics
| Factor |
Impact |
| Expanded indications |
Increased volume, potential for higher total revenue but pressure on per-dose price |
| Biosimilar development |
Likely to cause price erosion within 5-7 years |
| Reimbursement policies |
Will influence actual net prices; payers may negotiate discounts to control costs |
What Are the Key Market Drivers for Vyvgart?
-
Efficacy and Safety Profile
Vyvgart demonstrates significant symptom improvement with a favorable safety profile compared to immunosuppressants, which boosts prescribing confidence.
-
Regulatory Approvals
Besides the U.S., Vyvgart received conditional approval in Europe in 2022. Expanding approvals in other regions will grow the market.
-
Pipeline Progress
The development of Vyvgart for other autoimmune diseases like immune thrombocytopenia (ITP) and neuromyelitis optica may increase demand.
-
Pricing Power
The drug's high efficacy and limited competition allow for maintained price levels in the near term.
Summary of Market Projection Assumptions
| Assumption |
Explanation |
| Adoption rate |
Estimated to reach 70-80% among eligible gMG patients within 5 years |
| Dose frequency |
Monthly infusions, with potential for regimen optimization |
| Regional expansion |
Europe, Asia, and emerging markets gaining approvals within 1-3 years |
| Biosimilar impact |
Mild within first 5 years, more significant after 7 years |
Final Analysis
Vyvgart (NDC 62135-0819) maintains a high-value position within the autoimmune treatment sector, driven by an expanding target patient population and limited competition. Its current pricing, roughly $5,000-$6,000 per dose, appears sustainable in the short term. Long-term outlook depends on pipeline progress, regulatory expansion, biosimilar entry, and market penetration.
Key Takeaways
- Vyvgart's market size is projected to grow to over $1.8 billion globally, driven by increased adoption and indication expansion.
- Average pricing remains stable, averaging $5,250 to $6,000 per infusion, with annual costs around $60,000 to $70,000 per patient.
- Market competition from emerging FcRn inhibitors may reduce prices after 5 years.
- Reimbursement policies and healthcare provider acceptance will influence actual net prices.
- The drug’s future revenue is tied to pipeline successes and broader geographic approvals.
FAQs
1. How does Vyvgart compare with other gMG treatments in efficacy?
Vyvgart reduces pathogenic IgG antibodies rapidly, showing symptom improvement within weeks, with a safety profile comparable or superior to immunosuppressants.
2. What is the typical dosage and administration schedule?
It involves an initial IV infusion every two weeks for the first month, then monthly maintenance infusions.
3. Are there approved biosimilars or competitors?
As of early 2023, no biosimilars exist; next-generation FcRn inhibitors are in development but not yet approved.
4. How might regulatory changes impact its price?
Reimbursement policies favoring value-based care could pressure manufacturers to offer discounts, especially as more competitors enter the market.
5. What emerging indications could expand Vyvgart’s market?
Immune thrombocytopenia and neuromyelitis optica are key areas under clinical evaluation, potentially broadening the patient base.
Citations:
[1] MarketsandMarkets, "Myasthenia Gravis Market," 2022.
